Long-term efficacy of evolocumab in reducing lipids in EU subjects with and without type 2 diabetes: an analysis from the open-label extension OSLER studies
2016
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI